NCT03352466View on ClinicalTrials.gov

NasoShield Study of Safety and Immunogenicity

PHASE1CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

May 13, 2019

Study Completion Date

May 13, 2019

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

NasoShield

NasoShield is an adenovirus-vectored anthrax vaccine.

BIOLOGICAL

BioThrax

Commercially available anthrax vaccine

OTHER

Placebo

Normal saline

Trial Locations (2)

32934

Optimal Research, LLC, Melbourne

78209

ICON Early Phase Services, LLC, San Antonio

Sponsors

Lead Sponsor

Altimmune, Inc.
All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY

NCT03352466 - NasoShield Study of Safety and Immunogenicity | Biotech Hunter | Biotech Hunter